Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.43 |
| ▸ | RPS6KA5 | O75582 | 4/20 | 0.42 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29746864 | 1.00 | EGFR (0.43) | EGFRRPS6KA5RPS6KA4FGFR4PIK3CD | |
| SCHEMBL30668008 | 0.79 | ALDH1A1 (0.31) | PIK3CDALDH1A1CRHBPCRHR2 | |
| SCHEMBL26111376 | 0.78 | EGFR (0.52) | EGFRPIK3CDPIK3CA | |
| SCHEMBL31352848 | 0.78 | EGFR (0.52) | EGFRPIK3CDPIK3CA | |
| SCHEMBL10044572 | 0.74 | EGFR (0.43) | EGFRPIK3CDPIK3CACYP1A2ALDH1A1 | |
| SCHEMBL15885495 | 0.74 | PIK3CD (0.41) | EGFRPIK3CDPIK3CAALDH1A1 | |
| SCHEMBL1294228 | 0.72 | TDP1 (0.45) | PIK3CDTSHRALDH1A1CRHBPCRHR2 | |
| SCHEMBL31405448 | 0.71 | ALDH1A1 (0.37) | EGFRRPS6KA5RPS6KA4PIK3CDALDH1A1 | |
| SCHEMBL1320635 | 0.71 | ALDH1A1 (0.37) | EGFRRPS6KA5RPS6KA4PIK3CDALDH1A1 | |
| SCHEMBL29961230 | 0.71 | RPS6KA5 (0.44) | EGFRRPS6KA5RPS6KA4FGFR4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021083186-A1 | PIPERIDINAMINE COMPOUND CONTAINING FUSED RING PYRIMIDINE, PREPARATION METHOD THEREFOR AND USE THEREOF | 沈阳中化农药化工研发有限公司 | 2021-05-06 | — | — | WO | claimed |
| US-11584759-B2 | Macrocyclic kinase inhibitor | HITGEN INC. (CN) | 2023-02-21 | — | — | US | disclosed |
| EP-3783000-B1 | MACROCYCLIC KINASE INHIBITOR | HITGEN INC (CN) | 2022-07-06 | — | — | EP | disclosed |
| WO-2021083186-A1 | PIPERIDINAMINE COMPOUND CONTAINING FUSED RING PYRIMIDINE, PREPARATION METHOD THEREFOR AND USE THEREOF | 沈阳中化农药化工研发有限公司 | 2021-05-06 | — | — | WO | disclosed |
| EP-3630759-A1 | ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT | Centre National De La Recherche Scientifique (FR) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018215557-A1 | ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-11-29 | — | — | WO | disclosed |
| US-20090036430-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2009-02-05 | — | — | US | disclosed |
| US-20080004285-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004285-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | PNPO, TYMP, PNP | EGFR 3724/4885RPS6KA5 2501/4885RPS6KA4 3167/4885 |
| US-20090036430-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | PNPO, TYMP, PNP | EGFR 3724/4885RPS6KA5 2501/4885RPS6KA4 3167/4885 |
| US-11584759-B2 | Macrocyclic kinase inhibitor | MAP3K20, TNK2, NTRK1 | EGFR 165/4885RPS6KA5 141/4885RPS6KA4 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.